Tempus AI (NASDAQ:TEM) Stock Price Down 7.9% - Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s stock price traded down 7.9% during trading on Monday . The stock traded as low as $31.36 and last traded at $34.55. 3,300,319 shares changed hands during trading, a decline of 4% from the average session volume of 3,431,535 shares. The stock had previously closed at $37.52.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a research note on Tuesday. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. Piper Sandler reiterated a "neutral" rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Guggenheim assumed coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a "buy" rating and a $74.00 price target on the stock. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $56.36.

Tempus AI Stock Up 9.7 %

The business has a fifty day moving average of $47.68 and a two-hundred day moving average of $47.26. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other Tempus AI news, Director David R. Epstein sold 620 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 865,041 shares of company stock valued at $35,917,673 in the last three months.

Institutional Trading of Tempus AI

Several large investors have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI in the 3rd quarter valued at $1,367,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company's stock valued at $68,922,000 after buying an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI in the third quarter valued at about $2,726,000. Dakota Wealth Management purchased a new position in shares of Tempus AI in the third quarter worth about $1,185,000. Finally, Sigma Planning Corp acquired a new position in Tempus AI during the third quarter worth about $1,323,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.